AGILE THERAPEUTICS INC: Nasdaq/NYSE listing notice — Agile Therapeutics gets Nasdaq extension to Sept 25, 2023; must meet $2.5M equity rule

AGILE THERAPEUTICS INC

Received 180-day extension from Nasdaq; must regain compliance with $2.5M stockholders' equity by Sept 25, 2023.
Reported stockholders' equity of ($5.545M) as of Dec 31, 2022, below requirement.
Failure to demonstrate compliance by Sept 25 may lead to delisting; company intends to take measures.
Delisting could reduce liquidity, market price, and access to equity markets.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

AGILE THERAPEUTICS INC received a nasdaq extension granted notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: extension granted
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

(the “Stockholders’ Equity Requirement”). The Company’s Annual Report on Form 10-K for the fourth quarter and year ended December 31, 2022, reported stockholders’ equity of $(5,545,000), which is below the Stockholders’ Equity Requirement for continued listing on the Nasdaq Capital Market. The Company submitted a plan to regain compliance with the Stockholders’

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001558370-23-010792

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.